Dapagliflozin promotes metabolic reprogramming against myocardial infarction through the MAPK-FOXO3-STC1 and HIF-1a-STC1 pathways
Life Sciences · 2025-09 · 377 · 123798
DOI: 10.1016/j.lfs.2025.123798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2025-09. Verfasst von Xiaoliang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Development of Cardiovascular, The Beibei Affiliated Hospital of Chongqing Medical University, Chongqing 400700, China. Electronic address: 160612@ho…. Hauptthemen laut MEDLINE: Myocardial Infarction, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
BACKGROUND: Myocardial infarction (MI) results in mitochondrial dysfunction and metabolic imbalance, ultimately causing cellular injury and impaired cardiac function. Dapagliflozin (DAPA) has been shown to reduce cardiovascular mortality; however, the underlying mechanisms by which it confers cardioprotection in MI remain incompletely understood. METHODS: To explore the protective role of DAPA, an oxygen-glucose deprivation (OGD) model was established in H9c2 cardiomyoblasts to assess its effects on cell proliferation, apoptosis, metabolism, and mitochondrial function. A series of molecular assays, including qRT-PCR, Western blotting, chromatin immunoprecipitation (ChIP), dual-luciferase reporter analysis, and rescue experiments, were performed to elucidate the involvement of HIF-1α, FOXO3, and STC1 in DAPA-mediated responses. In vivo, the cardioprotective effects of DAPA were validated using a rat model of MI. RESULTS: DAPA promoted proliferation, inhibited apoptosis, and restored glucose uptake, ATP generation, and mitochondrial activity in OGD-treated H9c2 cells by modulating the JNK signaling pathway, promoting FOXO3 degradation, and engaging the HIF-1α-STC1 axis. In MI rats, DAPA significantly reduced infarct size, improved cardiac function, and alleviated myocardial fibrosis and apoptosis. Rescue experiments further confirmed that overexpression of STC1 potentiated DAPA's effects, whereas STC1 knockdown attenuated them. CONCLUSION: These findings indicate that the HIF-1α-FOXO3-STC1 pathway plays a central role in the cardioprotective mechanisms of DAPA. By modulating the MAPK-FOXO3-STC1 and HIF-1α-STC1 signaling cascades, DAPA improves mitochondrial function and metabolic homeostasis, supporting its therapeutic potential in the treatment of MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development of Cardiovascular, The Beibei Affiliated Hospital of Chongqing Medical University, Chongqing 400700, China. Electronic address: 160612@hospital.cqmu.edu.cn.
- Chongqing Municipal Center for Disease Control and Prevention, Chongqing 400707, China; Department of Disease Prevention and Control, Daping Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical…
- Development of Cardiovascular, The Beibei Affiliated Hospital of Chongqing Medical University, Chongqing 400700, China.
- Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
- Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: luosuxin@hospital.cqmu.edu.cn.
Förderung
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Zhang, X., Zhou, C., Chen, G., Li, Y., Liu, X., & Luo, S. (2025). Dapagliflozin promotes metabolic reprogramming against myocardial infarction through the MAPK-FOXO3-STC1 and HIF-1a-STC1 pathways. Life Sciences, 377, 123798. https://doi.org/10.1016/j.lfs.2025.123798
Vancouver
Zhang X, Zhou C, Chen G, Li Y, Liu X, Luo S. Dapagliflozin promotes metabolic reprogramming against myocardial infarction through the MAPK-FOXO3-STC1 and HIF-1a-STC1 pathways. Life Sciences. 2025;377:123798. doi:10.1016/j.lfs.2025.123798
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaoliang and Zhou, Chunbei and Chen, Guozhu and Li, Yuanzhu and Liu, Xiaorui and Luo, Suxin},
title = {Dapagliflozin promotes metabolic reprogramming against myocardial infarction through the MAPK-FOXO3-STC1 and HIF-1a-STC1 pathways},
journal = {Life Sciences},
year = {2025},
volume = {377},
pages = {123798},
doi = {10.1016/j.lfs.2025.123798}
}
EUVIMED